Alzheimer’s Disease

Blogs

Brain Awareness Week 2024: A Spotlight on Brain Health and New Treatments for Neurological Diseases
Biotech News

Biogen Shelves Contentious Alzheimer’s Drug Aduhelm
Approvals News

BrainSee AI-Powered Dementia Test Receives FDA Approval

Advancing Diversity in Alzheimer’s Disease (AD) Research: Innovative Strategies for Collaborative Solutions

November 20, 2023
Blogs

Insights into New Alzheimer’s Treatments: Treating Agitation and First THC-Based Therapeutic in Trials — Interview with IGC’s Ram Mukunda and Claudia Grimaldi – Xtalks Life Science Podcast Ep. 127

Revolutionizing Alzheimer’s Disease Clinical Trials Using a Blood-Based Diagnostic Test for Participant Identification

August 24, 2023
Diagnostics News

Quanterix’s LucentAD Test May Help with Early Diagnosis of Alzheimer’s

New Diagnostics and Emerging Biomarkers for Alzheimer’s Disease

August 24, 2023

Alzheimer’s and Biomarkers in Drug Development: The ABCD’s of Clinical Trial Innovation

July 10, 2023

Digital Endpoint Development for Alzheimer’s Disease: The Importance of Patients as Partners

May 23, 2023

Reducing Caregiver Burden in Alzheimer’s Disease Clinical Trials to Boost Patient Recruitment

May 24, 2023
Blogs

Amgen Launches Humira Biosimilar Amjevita + Potential New Blood Test for Early Detection of Alzheimer’s – Xtalks Life Science Podcast Ep. 96
Diagnostics News

Early Detection of Alzheimer’s Disease: New Research Shows How a Blood Test Could Lead to Earlier Diagnosis
Approvals News

Leqembi (lecanemab) Granted Accelerated Approval by the FDA as Alzheimer’s Disease Treatment

Bringing the Clinical Trial to the Patient in Preclinical Alzheimer’s Disease

December 15, 2022
Biotech News

Monoclonal Antibody Lecanemab Finalizing Clinical Trials for Alzheimer’s Disease Treatment